Home・Listă Acțiuni・Insmed

Insmed

Închisă

SectorSănătate

98.72 0.46

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

96.22

Maxim

99.38

Indicatori cheie
By Trading Economics
Venit	165M -164M
Vânzări	42M 306M
EPS	-0.76
Marjă de profit	-53.458
Angajați	1,664
EBITDA	164M -136M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+100.98% upside

Dividende
By Acuity
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-7.5B 23B
Deschiderea anterioară	98.26
Închiderea anterioară	98.72

Sentimentul știrilor

By Acuity

43%

57%

135 / 340 Clasament în Healthcare

Insmed Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31 iul. 2026, 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 iul. 2026, 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28 iul. 2026, 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27 iul. 2026, 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24 iul. 2026, 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22 iul. 2026, 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21 iul. 2026, 17:41 UTC

Social Media

News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20 iul. 2026, 19:16 UTC

News

Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Comparație

Modificare preț

Insmed Așteptări

Obiectiv de preț

By TipRanks

100.98% sus

Prognoză pe 12 luni

Medie 198.17 USD 100.98%

Maxim 243 USD

Minim 160 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruInsmed - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor Insmed - Dist în ultimele 3 luni.

Sentiment

By Acuity

135 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.